| Timetable |
| Download Conference Program |
| Download All Abstracts |
| Zoom Access |
| Corporate Program |
Oral Sessions
Day 2, June 23（Mon.） 11:40-11:55
Room B (Maesato Center)
- 2B-O1-1140
The discovery of clinical disease biomarkers by LC-MS-based global metabolomics
(1China Medical Uni., 2China Medical Univ. Hospit.)
oChao-Jung Chen1,2
Non-targeted liquid chromatography-mass spectrometry (LC-MS)-based metabolomics has been widely used for discovering novel biomarkers. We have used non-targeted metabolomics to discover urinary biomarkers of diabetes nephropathy, and plasma biomarkers of Alzheimer's disease and stroke. However, a low identification rate of metabolite biomarkers is still encountered because of incomplete databases and low dynamic quantification range in high resolution MS. Targeted metabolomics focus on specific biomarkers and can offer a high sensitivity; however, this approach usually limits the exploration of other novel biomarkers. To overcome the limitations from both non-targeted and targeted metabolomics, we propose a metabolomics approach for more comprehensively discovering clinical biomarkers. We applied this new approach to for discovering biomarkers for acute ischemic stroke. Comparing to our published results, in which the same clinical samples and untargeted metabolomics were used, our new approach can successfully discover more biomarkers with higher sensitivity and specificity, demonstrating its high potential in biomarker discovery and disease mechanism elucidation.